One headline acquisition, two different deals
When Wandercraft announced its acquisition of Ekso Bionics in early October, the public focus was on combining medical exoskeleton platforms such as Atalante X, EksoNR, Eve and Indego Personal. But the seller’s SEC disclosure shows that the industrial business followed a separate path.
ChronoScale states that on September 30, Ekso Bionics and its German subsidiary first sold substantially all assets of the EksoWorks industrial exoskeleton business, including the EVO product line, to DynaWear Tech. Immediately afterward, a ChronoScale subsidiary sold the remaining Ekso Bionics company, which held the neurorehabilitation business, to WanderEkso, a Wandercraft subsidiary.
The distinction matters to anyone who owns, evaluates, sells or services an industrial Ekso product. Wandercraft acquired the medical business, not the entire historical industrial portfolio.
The four medical systems referenced in Wandercraft’s announcement are Atalante X, EksoNR, Eve and Indego Personal. This does not imply that every industrial accessory or contract was transferred on identical terms.
DynaWear is the new industrial point of contact
Ekso’s own EVO page now carries a direct notice that the EksoWorks business is DynaWear Tech. The message says DynaWear will continue manufacturing and distributing EVO and providing support for ZeroG.
DynaWear’s official website presents EVO as a passive spring-assisted upper-body exoskeleton for repetitive shoulder and overhead work. It also lists ZeroG, a mechanical heavy-tool support arm used in demanding construction and maintenance tasks. ZeroG should not be presented as the same kind of body-worn exoskeleton as EVO.
The company identifies itself as a spinout formed by the former Ekso industrial team. That provides a continuity signal, but an asset sale and a new website alone do not establish unchanged service terms, distribution contracts, spare-parts arrangements or global warranty obligations. Those details should be confirmed with the supplier.
EVO manufacturing and distribution, with ZeroG support described on the company’s official channels.
Neurorehabilitation products and clinical relationships move through WanderEkso and Ekso Bionics.
Existing industrial and medical users should identify the correct product-specific support organization.
Why the ownership split matters commercially
Industrial exoskeleton buying decisions depend on fitting, technician training, safety documentation, spare parts, warranty handling and ongoing service. A change of ownership can be more consequential to an enterprise buyer than the initial acquisition headline suggests.
For an EVO customer, the useful question is no longer simply whether “Ekso Bionics” was acquired. It is where to obtain replacement components, field support or updated documentation for a device deployed at work.
Medical customers face a different continuity path. Wandercraft said its combined group would continue supporting the four named medical systems and the clinicians and users relying on them. That statement covers the medical portfolio discussed in its announcement and should not be automatically extended to the separated EksoWorks products.
Exoskeleton Index analysis
The story is not a reversal of the Wandercraft acquisition. It is a more precise map of what was acquired by whom.
The two-step sale illustrates why exoskeleton market consolidation must be analyzed at the asset and product-line level. A recognizable corporate name may conceal industrial and medical operations with different technology stacks, customers, support models and buyers.
For EI, this also exposes a data-maintenance issue. Our Ekso Bionics company profile and EVO product profile historically associate EVO with Ekso Bionics. The original manufacturer should remain part of the product’s provenance, but current commercial responsibility needs to distinguish DynaWear from Wandercraft’s medical business.
Our earlier Wandercraft acquisition report covers the medical combination; this report clarifies the industrial transaction.
What has and has not been confirmed
ChronoScale’s SEC filing confirms the two transactions and EVO asset sale. Ekso’s official product page identifies DynaWear as the current source for EVO manufacturing, distribution and ZeroG support.
The public materials reviewed do not provide a complete contract-by-contract transfer list, guaranteed warranty continuity for every customer, exact geographic distribution rights or the financial consideration for each transaction. Readers should contact DynaWear or the relevant medical supplier for product-specific arrangements.
What happens next
The next useful signals are whether DynaWear expands the EVO line, which distributor agreements remain active, how service and documentation migrate, and whether customers report a smooth transition.
For medical exoskeletons, the central question is how Wandercraft and Ekso Bionics integrate their clinical portfolios, regional support infrastructure and rehabilitation networks. The two tracks should now be assessed separately.
EI will continue tracking those changes across the manufacturing sector and the 2026 market analysis.
Sources and reporting notes
ChronoScale, SEC filing, October 2026. Sale of Legacy Ekso Business. Primary disclosure identifying the September 30 industrial asset sale and subsequent medical company sale.
Ekso Bionics official EVO page. EksoWorks is now DynaWear Tech, including the company’s statement on EVO and ZeroG support.
DynaWear Tech. Official product and company information for EVO, ZeroG and industrial applications.
Wandercraft, October 1, 2026. Official acquisition announcement detailing the medical portfolio and intended continued support.
Reporting note. The corporate transactions closed September 30. Subsequent disclosures clarified the ownership structure. This is not a newly completed transaction in late October.
